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Regulation of cholecystokinin (CCK) expression was studied in the human neuroepithelioma cell line SK-N-MCIXC. The cells were treated with 
the phosphodiesterase inhibitor isobutyl-methylxanthine and the tumor promoting phorbol ester, phorbol-1Zmyristate 13-acetate; activators of 
the cyclic AMP (CAMP) and protein kinase C (PKC) second messenger pathways, respectively. Levels of CCK mRNA were determined after 6, 
12 and 24 hour drug treatments, with Northern blot analysis using human CCK cDNA hybridization probes. Activation of both CAMP and PKC 
second messenger pathways increased CCK mRNA levels in SK-N-MCIXC cells. These results indicate that the levels of CCK mRNA in 
SK-N-MCIXC cells are regulated by CAMP and PKC dependent mechanisms. 
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1. INTRODUCTION 
The biologically active brain-gut peptide CCK is syn- 
thesized in a cell specific manner in the intestinal tract, 
the central nervous system (CNS) [l-3], the pituitary [4], 
and in male germ cells [5]. CCK is present in high con- 
centrations in several brain regions, including areas of 
the cerebral cortex, which are thought to mediate sen- 
sory, motor and associative processes [6,7]. A large 
number of studies indicate that brain CCK, predomi- 
nantly present as the octapeptide CCK-8, functions as 
a neurotransmitter or neuromodulator [8,9]. Several 
biological functions associated with central CCK in- 
clude effects that are directly related to the GI tract, for 
instance effects on gastric acid secretion, satiety and 
feeding behaviors [2,10-l 21. 
The role which CCK plays is linked to the mecha- 
nisms that regulate its biosynthesis and metabolism. 
Since processing and metabolic enzymes are distributed 
similarly throughout the brain, biosynthetic rates of 
peptide precursors are generally determined by cellular 
contents of their encoding mRNA’s [ 131. Northern blot 
analysis and in situ hybridization with specific gene 
probes have demonstrated that proCCK mRNAs are 
expressed in specific brain regions (referenced in Mon- 
stein et al. [14]). Additionaliy, Liddle et al. [15] found 
that stimulation of intestinal CCK secretion is associ- 
ated with an increase in CCK mRNA which results 
from increased CCK gene transcription. 
The abundance of CCK mRNA is determined by its 
stability and by the rate of transcription, regulated by 
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transcription factors, from its DNA template. In many 
eukaryotic cells, cell specific transcription factors are 
modulated through second messenger systems, primar- 
ily the cyclic adenosine 3’S’-monophosphate (CAMP) 
and protein kinase C (PKC) pathways. Both CAMP and 
phorbol ester response elements (CRE and TRE) have 
been identified and characterized on the rat CCK pro- 
moter/enhancer, located upstream of the mRNA initia- 
tion (CAP) site [16]. The DNA sequence of the rat and 
human CCK promoter/enhancer region is highly con- 
served [16], therefore CREs and TREs should also be 
present in the human CCK gene. 
In this study we investigated the effects of second 
messengers on CCK mRNA levels in the neuroepitheli- 
oma cell line SK-N-MCIXC, which was established 
after twice cloning the heterogeneous human neuro- 
epithelioma cell line SK-N-MC. The SK-N-MC cell line 
produces CCK specific mRNA; however, it exhibits 
poor postranslational processing of CCK prohormonal 
material, yielding only high molecular weight CCK pre- 
cursors and no immunoreactive CCK [17]. The SK-N- 
MCIXC cell line expresses the human CCK gene at very 
high levels and CCK-like peptides immunoreactive to a 
C-terminal CCK octapeptide antiserum are present in 
the cell line and its medium [18]. Additionally, SK-N- 
MCIXC cells cleave proCCK to completion (i.e. CCK- 
8) and demonstrate spontaneous and regulated release 
of CCK and CCK precursors [19]. This cell line should 
therefore provide a good in vitro model in which to 
study both the tissue-specific control of the induction of 
the CCK gene and the mechanisms responsible for the 
differential protein processing of the CCK precursor in 
neuronal systems. As a first step in examining the mech- 
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anisms which influence CCK biosynthesis in these cells 
we have measured mRNA levels in SK-N-MCIXC cell 
preparations in the presence of isobutylmethylxanthine 
(IBMX), 8-bromo-CAMP, phorbol- 12-myristate 13-ace- 
tate (PMA) and 4a-phorbol. 
2. MATERIALS AND METHODS 
2.1. Cell culture and drug treatment 
SK-N-MCIXC cells were plated in 172 cm2 culture flasks in RPM1 
containing 10% bovine calf serum, defined, non-iron supplemented, 
(Hyclone, Logan, Utah), 1% penicillin/streptomycin (Sigma, St. Louis, 
MO) and 1% non-essential amino acids (Irvine Scientific, Santa Ana, 
CA). The flasks were placed in a 37°C humidified incubator, with a 
5% CO2 atmosphere. The cells were split weekly with a hypo-osmolar 
solution [20]. The cell line was tested with the Gen-probe mycoplasma 
test kit (Gen-Probe Inc., San Diego, CA) and found to be negative for 
mycoplasma contamination. 
Approximately 2 million cells were plated in 100 x 20 mm tissue 
culture dishes, Falcon 3003 (Be&on Dickson Labware, Lincoln Park, 
NJ) and grown for 4 days prior to treatment. Cells were treated with 
fresh media supplemented with 0.5 mM IBMX, 0.5 @M PMA and 
dimethyl sulfoxide (DMSO) as a vehicle control, for 6, 12 and 24 h. 
In addition, 0.5 mM 8-bromo-CAMP and 0.5 PM 4cc-phorbol were 
used at the 12 h time point (all drugs purchased from Sigma, St. Louis, 
MO). Treatments were done in duplicate for each individual experi- 
ment. After the appropriate time the treated cells were lifted with a 
hypoosmolar solution, washed and resuspended in 1 ml of phosphate 
buffered saline. The cells were counted and 6 million cells were aliq- 
uoted into Eppendorf tubes for RNA isolation. 
2.2. Preparation of RNA and Northern blot analysis 
Total RNA was extracted from SK-N-MCIXC cells with an RNAid 
Plus Kit (BIO 101, La Jolla, CA). Cells were lysed with a guanidine 
isothiocyanate buffer and extracted with phenol-chloroform. RNA 
was further purified with RNAmatrix. The samples were precipitated 
with ethanol and resuspended in diethylpyrocarbonate (DEPC) 
treated H20. RNA in each sample was spectrophotometrically quanti- 
fied at 260 nm with a Beckman model 25 spectrophotometer. Purity 
of the samples was checked by an additional reading taken at 280 nm. 
Typically a ratio of 1.6-l .8 was obtained. 
Prior to electrophoresis RNA samples and RNA ladder (0.249.5 
kb; Gibco/BRL, Grand Island, NY) were treated with 0.7% (v/v) 
formaldehyde, 50% (v/v) deionized formamide and 1 x MOPS (20 mM 
4-morpholinepropanesulfonic a id, 5 mM sodium acetate, 1 mM 
EDTA, pH 7.0) for 15 min at 55°C. Ethidium bromide was added to 
RNA ladder samples prior to loading. Electrophoretic separation of 
RNA samples was performed on a 1% (w/v) agarose gel containing 
1 x MOPS and 6% (v/v) formaldehyde submerged in 1 x MOPS. The 
gel was run for 2 h at 100 mV, with the buffer circulated with a 
peristaltic pump. The RNA ladder was viewed on a short-wave UV 
box and the marker positions recorded. The samples were transferred 
to a Zeta-Probe GT nylon membrane (Bio-Rad, Richmond, CA) by 
capillary action with 6 x SSC (1 x SSC: 150 mM NaCl, 15 mM Na,- 
citrate . 2H,O). RNA was fixed to membranes by UV illumination in 
a UV Stratalinker 1800 (Stratagene, La Jolla, CA) using the Auto- 
crosslink function. 
2.3. Hybridization and cDNA probes 
The CCK probe was a 550 bp Ah&AluI fragment of exon 2 of the 
human CCK gene [21]. The /3-actin probe was a 1 kb chicken cDNA 
fragment. The cDNA probes were labeled using a Random Primed 
DNA Labeling Kit (Boehringer Mannheim Biochemica, Indianapolis, 
IN). [“P]dCTP, 3000 Ci/mmol (NEN, Boston, MA), was used to label 
the probe. 
Membranes were prehybridized in a heat sealing bag with a solution 
of 250 mM NaCl, 250 mM NaHPO,, 50% (v/v) deionized formamide 
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and 7% (w/v) sodium dodecyl sulfate (SDS) for 30 min at 43°C in a 
shaking water bath. Hybridization was carried out at 43°C for 12-16 
h in fresh buffer with 50 ng of [32P]dCTP labeled cDNA probe. The 
membranes were washed with vigorous shaking with 2 x SSC, 0.1% 
SDS and 0.5 x SSC, 0.1% SDS for 15 min each at 25°C. A final 15 min 
wash with 0.1 x SSC, 0.1% SDS was performed at 65°C with shaking. 
The moist membrane was sealed in a heat sealing bag and exposed to 
Kodak X-Omat AR scientific imaging film (Eastman Kodak Co., 
Rochester, NY) in a cassette with intensifying screens at -70°C for 
2-3 days. 
2.4. Data analysis and statistics 
Autoradiograms were analyzed using a Bio-Rad model 620 den- 
sitometer (Richmond, CA). CCK levels were standardized against 
/I-actin levels. Non-treated controls were normalized to 100. Second 
messenger t eated values were normalized against he controls. Statis- 
tical analysis was performed using the Student’s t-test for grouped 
data. Significance was set at P c 0.05. 
3. RESULTS 
To examine the affects of second messenger systems 
on CCK mRNA levels in SK-N-MCIXC cells, these 
cells were treated with activators of the CAMP or PKC 
regulatory systems. IBMX (0.5 mM), a phospho- 
diesterase inhibitor which elevates intracellular CAMP 
levels and 8-bromo-CAMP (0.5 mM), a non-hydrolyza- 
ble analog of CAMP, were used to investigate the effect 
of increasing CAMP levels on CCK mRNA in SK-N- 
MCIXC cells. PMA (0.5 PM) a tumor promoter and 
potential activator of phospholipase dependent PKC, 
was used to examine the effect of the PKC system on 
CCK mRNA levels. The cells were also treated with the 
inactive phorbol ester, 4a phorbol (0.5 PM), to deter- 
mine PMA specificity in this system. Additionally PMA 
and IBMX were added to the cells in combination, to 
reveal possible synergistic interactions between the two 
second messenger pathways. Cells were also treated 
with the DMSO vehicle. DMSO had no effect on CCK 
mRNA levels at any time point (6 h, n = 4, df = 6, 
t = 0.276, N.S.; 12 h, n = 4, df = 6, t = 0.271, N.S.; 24 h, 
n = 3, df = 4, t = 0.699, N.S.) Levels of CCK mRNA 
treatments were determined by Northern blot analysis 
with a human CCK cDNA hybridization probe (Fig. 1). 
Fig. 1. Northern blot analysis with a human CCK cDNA hybridiza- 
tion probe demonstrating CCK mRNA bands after 12 h treatments 
with control media, DMSO, IBMX, PMA and PMA in combination 
with IBMX. 
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Fig. 2. Activation of both CAMP and PKC second messenger path- 
ways increase CCK mRNA levels in SK-N-MCIXC cells. After 6 h 
treatments both PMA and IBMX raised the levels of CCK mRNA. 
PMA raised CCK levels 2.0-fold, IBMX raised the levels 1 .dfold and 
the drug combination increased CCK mRNA levels 2.8-fold when 
compared to non-drug treated controls. 
Our results demonstrate that activation of both 
cAMP and PKC second messenger pathways increases 
CCK mRNA levels in SK-N-MCIXC cells. After 6 h 
treatments (Fig. 2) both PMA and IBMX raised CCK 
mRNA levels. PMA raised the levels 2.0-fold (n = 4, 
df = 6, t = 1.605, N.S.) in comparison to controls, 
IBMX raised CCK levels 1.6-fold (n = 4, df = 6, 
t = 1.072, N.S.). The two drugs in combination in- 
creased CCK mRNA levels 2.8fold (n = 4, df = 6, 
t = 1.784, N.S.). 
After 12 h treatments (Fig. 3) our results were similar 
to those seen at 6 h. PMA increased CCK mRNA levels 
in SK-N-MCIXC cells appro~mately 2.5fold (n = 4, 
df = 6, t = 5.949, P < O.Ol), IBMX raised the levels 1.8- 
fold (n = 3, df = 4, t = 2.758, P c O.OS), and the drug 
l t 
combination increased CCK mRNA levels 2.7-fold 
(n = 3, df = 4, t = 4.615, P < 0.01) (Fig. 3). At the 12 h 
time point we did two additional treatments. To the test 
the affect of a second activator of the CAMP pathway 
we treated the cells with 8-bromo-CAMP, this produced 
a l.Cfold increase in CCK mRNA levels (n = 3, df = 4, 
t = 3.053, P < 0.05) (Fig. 3). We also treated the cells 
with 4a phorbol, as expected this drug had no effect on 
CCK mRNA levels (n = 3, df = 4, t = 0.562, N.S.) 
(Fig. 3). 
At 24 h we continue to see an increase in response to 
both PMA and IBMX. However, the value for PMA, 
a 1.6-fold increase compared to the control, starts to 
decrease (n = 3, df = 4, t = 1.185, N.S.) in relation to 
CCK mRNA levels in response to PMA after 6 and 
12 h treatments. Conversely, IBMX increased CCK 
mRNA levels in SK-N-MCIXC cells approximately 
2.5-fold (n = 4, df = 6, t = 5.949, P < 0.01) somewhat 
higher than at previous time points. PMA combined 
with IBMX raised CCK mRNA levels 3.3-fold (n = 3, 
df = 4, t = 5.206, P < 0.01) compared to controls. 
4. DISCUSSION 
Recently, Haun and Dixon [ 161 found that the rat 
CCK promoter/enhancer egion contains CREs and 
TREs. Sequence homology between the promoter/en- 
hancer region of rat and human CCK suggests that 
these elements would also be present in the human CCK 
gene. The results in this paper demonstrate that second 
messengers affect the abundance of CCK mRNA in the 
homogenous human neuroepithelioma cell line SK-N- 
MCIXC. The increase in CCK mRNA levels is most 
likely due to increased CCK gene transcription and sug- 
gests that SK-N-MCIXC cells contain both CREs and 
TREs. Our values for CCK mRNA levels in response 
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Fig. 3. Twelve hour histogram demonstrating increased CCK mRNA 
levels in response to PMA @S-fold), IBMX (l.&fold), 8-bromo- 
cAMP (1 .Cfold), and the PMA/IBMX combination (2.7-fold). Four 
a-phorbol had no effect on CCK mRNA levels. *P < 0.05, **P < 0.01. 
P conm IBMX PMA+IBMX 
OSmM 0.5pM,O.smM 
Fig. 4. At 24 h CCK mRNA levels in response to PMA (1.6-fold), 
IBMX (2.6-fold) and the drug combination (3.3-fold) are still in- 
creased relative to the control. At this time however, the value for 
PMA has begun to decrease when compared to PMA values after 6 
and 24 h. *PC 0.05; **PC 0.01. 
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Monstein and Folkesson [22] in the heterogeneous cell 
line SK-N-MC. However, when these activators were 
added in combination to SK-N-MCIXC cells they did 
not produce an additive response, whereas in SK-N- 
MC cells there was an approximate 2.5fold increase 
over either individual drug, after 12 h treatments [22]. 
These results indicate that SK-N-MCIXC cells do not 
respond additively to these drugs at the concentrations 
tested, or CCK mRNA levels in SK-N-MCIXC cells 
reach a maximum response, of approximately a 3-fold 
increase over controls, under these experimental condi- 
tions. 
Presently information on the control of CCK gene 
induction or the mechanisms responsible for protein 
processing of the CCK precursor at different anatomi- 
cal loci of CCK production is limited at the molecular 
biological level. It is important to identify the mecha- 
nisms that control the induction of the CCK gene and 
additionally to further clarify the molecular and physio- 
logical control mechanisms responsible for protein 
processing of CCK precursors, both peripherally and in 
the CNS. Although ultimately these questions hould be 
approached in vivo, the SK-N-MCIXC cell line; which 
unlike the parental SK-N-MC cell line, not only ex- 
presses CCK prohormonal material, but also carries out 
posttranslational peptide processing [17,191; is a unique 
model system in which we can begin to elucidate some 
of the mechanisms involved in neuronal CCK expres- 
sion and processing. 
SK-N-MCIXC cells, in addition to expressing CCK 
mRNA, demonstrate regulated and constitutive release 
of proCCK and its cleaved products, including CCK- 
58, CCK-22 and CCK-8 [19]. These cells also contain 
mRNA for the intracellular processing enzymes pro- 
hormone convertase 1 and 2 (PC], PC2) and furin [ 191 
which preferentially cleave prohormones at the car- 
boxy1 side of pairs of basic amino acid residues [23-251. 
The presence of PCl, PC2 and furin mRNA in SK-N- 
MCIXC cells suggests that they may cleave at the diba- 
sic amino acid pair Arg-Arg of the C-terminal part of 
proCCK, as is predicted from the most frequent propro- 
tein processing site motifs [26]; or they may also cleave 
at an Arg-X-X-Arg arrangement, a special class of 
paired basic amino acid residue-processing motif, which 
is present at the N-terminal of CCK-58 in the proCCK 
sequence. Distribution of mouse PC2 (mPC2) tran- 
scripts in the cortical and subcortical areas of the brain 
also suggests an involvement of mPC2 in the processing 
of proCCK [27]. 
Additionally, SK-N-MCIXC cells also express the 
extracellularly localized, membrane-associated CCK- 
metabolizing enzyme neutral endopeptidase 24.1 I, 
which is also present in rat cerebral cortex rich in CCK 
and other brain regions high in CCK [19]. In light of the 
above information and the results from this study, we 
believe that SK-N-MCIXC cell line is a good tool to 
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study drug, neurotransmitter and steroid effects on neu- 
ronal CCK biogenesis and processing. 
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